Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- ChecktodayChange DetectedTel Litwinsky, Israel, 52621 was added as a study site. Qiryat Krinitzi, Israel, 52621 was removed from the participating locations.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study locations were updated by adding Qiryat Krinitzi, Israel, 52621 and removing Tel Litwinsky, Israel, 52621; the page revision was updated from v3.6.5 to v3.6.6.SummaryDifference0.0%

- Check21 days agoChange DetectedAn NIH grant/contract identifier was added to the study's list of Other Study ID Numbers, linking the trial to U.S. NIH funding.SummaryDifference0.0%

- Check28 days agoChange DetectedAdded contact details for the study locator service, including an email address and phone number, to facilitate outreach and inquiries regarding the study.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page revision was bumped from v3.6.4 to v3.6.5, signaling a newer page version. This is a metadata update rather than a substantive change to the study details.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor update to the page version rather than substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.